Evaxion Biotech A/S

NasdaqCM EVAX

Evaxion Biotech A/S Net Income for the year ending December 31, 2023: USD -22.12 M

Evaxion Biotech A/S Net Income is USD -22.12 M for the year ending December 31, 2023, a 4.51% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.

Evaxion Biotech A/S Net Income for the year ending December 31, 2022 was USD -23.17 M, a 5.56% change year over year.
Evaxion Biotech A/S Net Income for the year ending December 31, 2021 was USD -24.53 M, a -63.35% change year over year.
Evaxion Biotech A/S Net Income for the year ending December 31, 2020 was USD -15.02 M, a -34.15% change year over year.
Evaxion Biotech A/S Net Income for the year ending December 31, 2019 was USD -11.20 M, a -102.26% change year over year.

Key data

Date	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)	Net Income Margin

NasdaqCM: EVAX

Evaxion Biotech A/S

CEO	Mr. Christian Kanstrup M.Sc.
IPO Date	Feb. 5, 2021
Location	Denmark
Headquarters	Dr. Neergaards Vej
Employees	49
Sector	Healthcare
Industries Biotechnology Vaccines

Description

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Key trends

Past 5 years